| abstract |
Provided herein are amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate, and pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the composition can be administered orally to a patient in a fed or fasted state, with a reduction or elimination of the effect of food. Preferably, there is no substantial difference in the pharmacokinetic parameters (eg Cmax , AUCo -t and/or AUCo -infinity ) of nilotinib following oral administration of the pharmaceutical composition, regardless of whether the pharmaceutical composition is in Subjects were administered in a fed or fasted state. |